Stereotactic Core Ablative Radiation Therapy (SCART) -  principal and practice of a novel strategy to treat bulky tumor

Author:

Yang Jun1,yan Weisi2,Lu Qiuxia3,Li Yuan3,Han Liangfu1,Wang Lei1,Qi Weihua1,Yuan Jie3,Chen Bingguang3,Wang Brian1

Affiliation:

1. Junxin Oncology Grup

2. University of Kentucky

3. Foshan Chancheng Hospita

Abstract

Abstract

Purpose: Bulky tumor is a challenge to surgery, chemotherapy, and conventional radiation therapy. In this study, we propose a novel therapeutic paradigm using the strategy of Stereotactic Core Ablative Radiation Therapy (SCART), which delivers an ablative dose to a large core of the bulky tumor and a relative low dose at tumor periphery. Methods and Materials: We pre-defined SCART-treatment volume (STV) at the core of bulky gross tumor volume (GTV) and irradiated with ablative dose. The remaining GTV surrounding STV was defined as Transitional Treatment Volume (TTV). SCART planning process was standardized. Linac-based VMAT, Cyberknife technique, and 6MV photon were adopted. Numerous radiation fields passed TTV, intersected within STV, and generated an ultra-heterogeneous dose distribution, including an ablative dose at STV. The dose quickly fell off at TTV and reached a low and safe level at the edge of GTV, sparing the surrounding tissue. Results: In Phase 1 trial, 19 patients with 21 biopsy-proven recurrent or metastatic bulky tumors were enrolled. The five dose levels were 15Gy X1, 15Gy X3, 18GyX3, 21GyX3, and 24GyX3; the GTV’s peripheral dose was limited at 5Gy per fraction. All patients completed treatment with average beam-on time of 8.9min and average treatment time of 18.5min. Mean follow-up time is 15.4 month. No grade-III or higher toxicity was observed. 7/19 patients still survive, with the overall survival of 40% at 30 months. Mean tumor volume shrinks by 60% between initial 301cc and post-SCART volumes of 118cc. Long follow-up showed that 14/21 tumors achieved PR, 2/21 CR, 3/21 SD, and 1/21 PD, leading to an encouraging local control of 95%. Conclusion: SCART emerges as a safe and effective strategy for treating bulky malignant tumors, demonstrating excellent local control and overall survival. Multiple treatment courses were feasible. The results from phase-1 study suggest that SCART could revolutionize the treatment landscape for bulky tumors, offering a promising avenue for further exploration and application in clinical practice.

Publisher

Springer Science and Business Media LLC

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3